Send to a Friend Font Size: Increase Decrease

Bill & Melinda Gates Foundation Trust

Bill & Melinda Gates Foundation Trust's Portfolio

Ticker	# of Shares	Price	Value
MSFT	39,264,670	$401.12	$15,749,844,431
BRK-B	25,142,853	$404.35	$10,166,512,611
	6,981,664	$1,141.93	$7,972,571,572
WM	35,234,344	$207.17	$7,299,499,047
CNI	54,826,786	$127.77	$7,005,218,448
	2,500,000	$1,141.93	$2,854,825,000
CAT	7,353,614	$355.04	$2,610,827,115
DE	3,917,693	$400.36	$1,568,487,570
ECL	5,218,044	$218.52	$1,140,246,975
KOF	6,214,719	$93.27	$579,646,842
View Additional Portfolio Information »

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people - especially those with the fewest resources - have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

Login to help us fill in information about this entity.

Inovio Pharma (INO) Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Brazil Aug 26, 2021 08:01AM

Inovio Pharma (INO) Announces Partnership Expansion with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800 Jun 8, 2021 08:11AM

Inovio Pharma (INO) to Develop DNA-encoded Monoclonal Antibody Candidates to Treat COVID-19 with Funding from DARPA and DoD Joint Program Dec 15, 2020 08:05AM

INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Jo Dec 15, 2020 08:00AM

Inovio Pharma (INO) Adds Thermo Fisher Scientific (TMO) To Global Manufacturing Consortium Sep 8, 2020 08:06AM

Jun 30, 2020 07:37AM Inovio Pharma (INO) Reports Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
Jun 24, 2020 07:07PM Exclusive: Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines
Jun 23, 2020 07:32AM Inovio Pharma (INO) Secures $71M Contract from U.S. DoD to Scale Up Manufacture of CELLECTRA 3PSP Smart Device & Procurement of CELLECTRA 2000 for COVID-19 DNA Vaccine
Apr 28, 2020 08:03AM Inovio Pharma (INO) Completes Enrollment in Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
Apr 6, 2020 08:32AM Inovio Pharma (INO) Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine
Apr 6, 2020 08:30AM INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
Mar 12, 2020 04:05PM INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
Mar 12, 2020 09:32AM Pre-Open Movers 03/12: (CEMI) (INO) (APT) Higher; (ZAGG) (NCLH) (CCL) Lower (more...)
Mar 12, 2020 08:07AM Inovio Pharma (INO) Announces $5M Bill & Melinda Gates Foundation Grant for COVID-19 Vaccine Smart Delivery Device
Jul 16, 2019 04:06PM Inovio Pharma (INO) sharpens focus on HPV-related diseases, cut selected early-stage R&D programs
May 9, 2019 04:05PM Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results
Mar 12, 2019 04:10PM Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results
Mar 5, 2019 08:00AM Inovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019
Mar 4, 2019 08:03AM Inovio Pharma (INO) Commences REVEAL 2 Global Phase 3 Clinical Study for the Treatment of HPV-Related Cervical Pre-cancer
Mar 4, 2019 08:00AM Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
Jan 24, 2019 08:46AM Inovio Pharma (INO) Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
Jan 24, 2019 08:32AM Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
Nov 26, 2018 08:02AM Inovio Pharma (INO) Shows Potency of its DNA-Encoded Monoclonal Antibody Platform in Three Preclinical Publications
Dec 22, 2016 07:26AM Inovio Pharma (INO): Zika Phase I Promising With More Data Coming - HC Wainwright
Dec 21, 2016 08:59AM Inovio Pharma (INO) Says Its Zika Vaccine Generates Robust Immune Responses
Dec 1, 2016 09:06AM Inovio Pharma (INO) Receives $6.1M Sub-Grant from The Wistar Institute for Zika Infection Treatment
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential
Oct 4, 2016 01:13AM Zika vaccine race spurred by crisis and profit potential

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed